![](https://ml.globenewswire.com/media/b5f3a22c-6ce8-4ec0-a070-701995cd7c81/small/onconova-logo-blue-jpg.jpg)
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational preparations for the narazaciclib program and the …